Is NMIBC up or down today?
NMIBC is down 0.15% today, last at 218.28. This stock moved -0.15% versus the prior close.
NMIBC · NMIBC
NMIBC (NMIBC) is trading at 218.28, down 0.15% on the session. NMIBC sits at the 50% mark of its 52-week range, carries a 14-day RSI of 60, and trades above its 50-day average. Over the past month it is up 1.23%.
Leading the coverage: “NDA Is Submitted for UGN-103 for Recurrent Low-Grade Intermediate-Risk NMIBC - OncLive” (Google News Company, 26d ago). NMIBC is +0.94% since story.
NMIBC trades on a trailing P/E of 11.5 and is running 2.29% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
NMIBC is down 0.15% today, last at 218.28. This stock moved -0.15% versus the prior close.
Leading the coverage: “NDA Is Submitted for UGN-103 for Recurrent Low-Grade Intermediate-Risk NMIBC - OncLive” (Google News Company, 26d ago). NMIBC is +0.94% since story. Dominant story: Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha (1 source, neutral) RSI is 60 — leaning bullish Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (181 days) · Drag or scroll left for earlier dates
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
Dabogratinib Elicits Responses in FGFR3+ Low-Grade Intermediate-Risk NMIBC - OncLive
NDA Is Submitted for UGN-103 for Recurrent Low-Grade Intermediate-Risk NMIBC - OncLive
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC - OncLive
Cretostimogene Grenadenorepvec Shows Complete Responses in NMIBC - CancerNetwork